US3489769A - 1-substituted-3-aroyl-pyrrolidines - Google Patents
1-substituted-3-aroyl-pyrrolidines Download PDFInfo
- Publication number
- US3489769A US3489769A US738414A US3489769DA US3489769A US 3489769 A US3489769 A US 3489769A US 738414 A US738414 A US 738414A US 3489769D A US3489769D A US 3489769DA US 3489769 A US3489769 A US 3489769A
- Authority
- US
- United States
- Prior art keywords
- mole
- ether
- solution
- mixture
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 82
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 57
- 239000000203 mixture Substances 0.000 description 47
- 239000000243 solution Substances 0.000 description 45
- -1 aryllower-alkyl Chemical group 0.000 description 40
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- 150000003839 salts Chemical class 0.000 description 30
- 150000001875 compounds Chemical class 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 26
- 239000002904 solvent Substances 0.000 description 25
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 24
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 22
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 22
- 239000004480 active ingredient Substances 0.000 description 19
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 15
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 14
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 13
- 235000019341 magnesium sulphate Nutrition 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 239000000284 extract Substances 0.000 description 12
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 12
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 239000012458 free base Substances 0.000 description 11
- 238000010992 reflux Methods 0.000 description 11
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 10
- 229920002472 Starch Polymers 0.000 description 10
- 239000008101 lactose Substances 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- 239000008107 starch Substances 0.000 description 10
- 235000019698 starch Nutrition 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 125000000217 alkyl group Chemical group 0.000 description 8
- 235000019270 ammonium chloride Nutrition 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 230000007062 hydrolysis Effects 0.000 description 8
- 238000006460 hydrolysis reaction Methods 0.000 description 8
- 150000004658 ketimines Chemical class 0.000 description 8
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 7
- 238000009835 boiling Methods 0.000 description 7
- 239000011777 magnesium Substances 0.000 description 7
- 229910052749 magnesium Inorganic materials 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- ANRQGKOBLBYXFM-UHFFFAOYSA-M phenylmagnesium bromide Chemical compound Br[Mg]C1=CC=CC=C1 ANRQGKOBLBYXFM-UHFFFAOYSA-M 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- TXHIDIHEXDFONW-UHFFFAOYSA-N benzene;propan-2-one Chemical compound CC(C)=O.C1=CC=CC=C1 TXHIDIHEXDFONW-UHFFFAOYSA-N 0.000 description 5
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 5
- 235000013539 calcium stearate Nutrition 0.000 description 5
- 239000008116 calcium stearate Substances 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 5
- 239000000391 magnesium silicate Substances 0.000 description 5
- 229910052919 magnesium silicate Inorganic materials 0.000 description 5
- 235000019792 magnesium silicate Nutrition 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- GEVPUGOOGXGPIO-UHFFFAOYSA-N oxalic acid;dihydrate Chemical compound O.O.OC(=O)C(O)=O GEVPUGOOGXGPIO-UHFFFAOYSA-N 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- RYCQUUNQHVAFSM-UHFFFAOYSA-N 1-benzylpyrrolidine-3-carbonitrile Chemical compound C1C(C#N)CCN1CC1=CC=CC=C1 RYCQUUNQHVAFSM-UHFFFAOYSA-N 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 4
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 4
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 240000006394 Sorghum bicolor Species 0.000 description 4
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 4
- 235000009430 Thespesia populnea Nutrition 0.000 description 4
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 4
- 239000001506 calcium phosphate Substances 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 4
- 229940038472 dicalcium phosphate Drugs 0.000 description 4
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 239000012258 stirred mixture Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- QHNFSJQLFADUKQ-UHFFFAOYSA-N (1-ethylpyrrolidin-3-yl)-phenylmethanone Chemical compound C(C1=CC=CC=C1)(=O)C1CN(CC1)CC QHNFSJQLFADUKQ-UHFFFAOYSA-N 0.000 description 3
- BTANRVKWQNVYAZ-SCSAIBSYSA-N (2R)-butan-2-ol Chemical compound CC[C@@H](C)O BTANRVKWQNVYAZ-SCSAIBSYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- 150000004792 aryl magnesium halides Chemical class 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000012259 ether extract Substances 0.000 description 3
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- QXYSYYCPALRMRV-UHFFFAOYSA-N 1-methylpyrrolidine-3-carbonitrile Chemical compound CN1CCC(C#N)C1 QXYSYYCPALRMRV-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 2
- 239000003929 acidic solution Substances 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000003529 anticholesteremic agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 150000005840 aryl radicals Chemical class 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 2
- PAEXAUSGWPUEHB-UHFFFAOYSA-N ethyl 3-benzoylpyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OCC)CCC1C(=O)C1=CC=CC=C1 PAEXAUSGWPUEHB-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- YHWIEKHEXRGFTR-UHFFFAOYSA-N (1-benzylpyrrolidin-3-yl)-(4-fluorophenyl)methanone Chemical compound C1=CC(F)=CC=C1C(=O)C1CN(CC=2C=CC=CC=2)CC1 YHWIEKHEXRGFTR-UHFFFAOYSA-N 0.000 description 1
- FEHNISZCWCXRKX-UHFFFAOYSA-N (1-methylpyrrolidin-3-yl)-phenylmethanone Chemical compound C1N(C)CCC1C(=O)C1=CC=CC=C1 FEHNISZCWCXRKX-UHFFFAOYSA-N 0.000 description 1
- YAUUECFHRSHLAF-UHFFFAOYSA-N (4-fluorophenyl)-pyrrolidin-1-ylmethanone Chemical compound C1=CC(F)=CC=C1C(=O)N1CCCC1 YAUUECFHRSHLAF-UHFFFAOYSA-N 0.000 description 1
- UISSKLNYXVTSHO-UHFFFAOYSA-N 1-[4-(3-bromopropoxy)-3-methoxyphenyl]ethanone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCBr UISSKLNYXVTSHO-UHFFFAOYSA-N 0.000 description 1
- NNMBNYHMJRJUBC-UHFFFAOYSA-N 1-bromo-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC(Br)=C1 NNMBNYHMJRJUBC-UHFFFAOYSA-N 0.000 description 1
- PLDWAJLZAAHOGG-UHFFFAOYSA-N 1-bromo-3-methoxybenzene Chemical compound COC1=CC=CC(Br)=C1 PLDWAJLZAAHOGG-UHFFFAOYSA-N 0.000 description 1
- PTCKTBHNJVBPGW-UHFFFAOYSA-N 1-cyclohexylpyrrolidine-3-carbonitrile Chemical compound C1C(C#N)CCN1C1CCCCC1 PTCKTBHNJVBPGW-UHFFFAOYSA-N 0.000 description 1
- WVXBJIJBNVYZCD-UHFFFAOYSA-N 1-propan-2-ylpyrrolidine-3-carbonitrile Chemical compound CC(C)N1CCC(C#N)C1 WVXBJIJBNVYZCD-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- XKTYXVDYIKIYJP-UHFFFAOYSA-N 3h-dioxole Chemical compound C1OOC=C1 XKTYXVDYIKIYJP-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- OFEKSUIIKTWFTC-UHFFFAOYSA-N [1-(2-ethoxyethyl)pyrrolidin-3-yl]-(4-fluorophenyl)methanone Chemical compound C1N(CCOCC)CCC1C(=O)C1=CC=C(F)C=C1 OFEKSUIIKTWFTC-UHFFFAOYSA-N 0.000 description 1
- WSWOKFODOPIESP-UHFFFAOYSA-M [Br-].FC(F)(F)C1=CC=CC([Mg+])=C1 Chemical compound [Br-].FC(F)(F)C1=CC=CC([Mg+])=C1 WSWOKFODOPIESP-UHFFFAOYSA-M 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 235000014590 basal diet Nutrition 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- LJQKCYFTNDAAPC-UHFFFAOYSA-N ethanol;ethyl acetate Chemical compound CCO.CCOC(C)=O LJQKCYFTNDAAPC-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- YKWNUSJLICDQEO-UHFFFAOYSA-N ethoxyethane;propan-2-ol Chemical compound CC(C)O.CCOCC YKWNUSJLICDQEO-UHFFFAOYSA-N 0.000 description 1
- 125000006332 fluoro benzoyl group Chemical group 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-M isobutyrate Chemical compound CC(C)C([O-])=O KQNPFQTWMSNSAP-UHFFFAOYSA-M 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- 125000006178 methyl benzyl group Chemical group 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- YLBMMUDQGTXXKP-UHFFFAOYSA-N phenyl(pyrrolidin-3-yl)methanone Chemical compound C=1C=CC=CC=1C(=O)C1CCNC1 YLBMMUDQGTXXKP-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- MWWATHDPGQKSAR-UHFFFAOYSA-N propyne Chemical compound CC#C MWWATHDPGQKSAR-UHFFFAOYSA-N 0.000 description 1
- 150000003235 pyrrolidines Chemical class 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 150000003335 secondary amines Chemical group 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
Definitions
- the present invention describes l-substituted 3-aroylpyrrolidines which have been shown to be useful in lowering plasma cholesterol levels.
- the compounds are prepared from l-substituted-3cyanopyrrolidines by reaction with aryl magnesium halides.
- R is hydrogen, lower alkyl, aryllower-alkyl, aryloxy,
- R is hydrogen, lower alkoxy, trifluoromethyl, halogen having an atomic weight less than 80, and lower alkyl, and acid addition salts thereof.
- the compounds of the invention having the foregoing Formula I are generally characterized by important pharmacological activity and are eifective as hypocholesterolemic agents and, as such, are particularly useful in lowering plasma cholesterol levels in living animal bodies as demonstrated in rats.
- lower alkyl as used herein includes straight and branched chain radicals of up to eight carbon atoms inclusive, preferably no more than six carbon atoms, and is exemplified by such groups as methyl, ethyl, propyl, isopropyl, butyl, sec. butyl, tertiary butyl, amyl, isoamyl, hexyl, heptyl, octyl and the like.
- a lower-alkoxy group has the formula O-lower-alkyl.
- lower cycloalkyl as used herein includes primarily cyclic radicals containing three up to nine carbon atoms inclusive and encompasses such groups as cyclopropyl, cyclobutyl, cyclohexyl, cyclopentyl, methylcyclohexyl, propylcyclohexyl, ethylcyclopentyl, propylcyclopentyl, dimethylcyclohexyl, cycloheptyl, and cyclooctyl.
- lower alkylene has the formula (CH wherein m is a positive integer from l-4 inclusive.
- aryllower-alkyl are lower-alkyl substituted phenyl groups such as benzyl, phenethyl, methylbenzyl, phenpropyl and the like.
- An aryl radical refers to the. phenyl radical alone or to a phenyl radical substituted by any radical or radicals which are not reactive or otherwise interfering under the conditions of reaction, such radicals including lower alkoxy, lower alkyl, trifiuoromethyl, halo and the like.
- the aryl radicals have preferably no more than one to three substituents such as those given above and, furthermore, these substituents can be in various available positions of the aryl nucleus and, when more than one substituent is present, can be the same or different and can be in various position combinations relative to each other.
- An aroyl radical has the formula
- An aryloxy radical has the formula O-aryl.
- This invention also includes acid addition salts of the above defined bases formed with nontoxic organic and inorganic acids.
- Such salts are easily prepared by methods known in the art.
- the toxicity or nontoxicity of the salt is immaterial; when the compounds are to be used as pharmaceuticals, they are most conveniently used in the form of nontoxic acid-addition salts. Both toxic and nontoxic salts are therefore within the purview of the invention.
- the acids which can 'be used to prepare the preferred nontoxic acid-addition salts are those which produce, when combined with the free bases, salts whose anions are relatively innocuous to the animal organism in therapeutic doses of the salts, so that beneficial physiological properties inherent in the free bases are not vitiated by side effects ascribable to the anions.
- the base is reacted with the calculated amount of organic or inorganic acid in aqueous miscible solvent, such as ethanol or isopropanol, with isolation of the salt by concentration and cooling, or the base is reacted with an excess of the acid in aqueous immiscible solvent, such as ethyl ether or isopropyl ether, with the desired salt separating directly.
- aqueous miscible solvent such as ethanol or isopropanol
- organic salts are those formed with maleicQ-fumaric, benzoic, ascorbic, pamoic, succinic, methanesulfonic, acetic, propionic, tartaric, citric, lactic, malic, citraconic, itaconic, hexamic, p-arninobenzoic, glutamic, stearic acid and the like.
- inorganic salts are those formed with hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric and nitric acids.
- novel compounds of this invention as represented by Formula I are prepared from 1-R-3-cyanopyrrolidines prepared as described in US. Patent 3,318,908.
- a l-R-3-cyanopyrrolidine of Formula II, wherein R is lower alkyl, lower cycloalkyl, aryl and phenyllower-alkyl is reacted in a dry inert organic solvent, preferably ether, with an arylmagnesium halide to give a 1-R-3-aroylpyrrolidine of Formula III, wherein R is as defined immediately hereinabove.
- the 1-benzyl-3-aroylpyrrolidine of Formula III prepared from 1-benzyl-3-cyanopyrrolidine and an arylmagnesium halide is reacted with an excess of cyanogen bromide in a dry inert organic solvent, illustratively chloroform, to give a 1-cyano-3-aroylpyrrolidine which generally is not isolated, and is hydrolyzed with dilute hydrochloric acid for a period of from about 12 hours to about 16 hours to give a 1-carbamoyl-3-aroylpyrrolidine.
- the latter compound is further hydrolyzed with concentrated hydrochloric acid for a periodof from 48 hours to about 72 hours to give a 3-aroylpyrrolidine.
- concentrated hydrochloric acid for a periodof from 48 hours to about 72 hours to give a 3-aroylpyrrolidine.
- the residual crude material remaining after evaporation of the chloroform solvent following the reaction described above with cyanogen bromide can be hydrolyzed directly to the 3-aroylpyrrolidine using concentrated hydrochloric acid.
- 3-aroylpyrrolidines can also be prepared by another method as follows:
- the 3-aroylpyrrolidines prepared by the methods described hereinabove constitute novel compounds of Formula I which are especially useful in preparing other novel and useful compounds within the scope of Formula I.
- the hydrogen atom of the secondary amine group of the pyrrolidine nucleus exhibits all the reactive properties of a secondary amino group and enters readily into conventional displacement reactions with a variety of reactive compounds, including, for example, alkyl halides, aralkyl halides, N-mono and N,N-disubstituted carbamoyl halides, arylsulfonyl halides, and the like.
- the 3-aroylpyrrolidines prepared as described above are reacted with compounds containing reactive halogen atoms in a lower alkanol solvent, illustratively ethanol, containing an alkali metal salt as, for example, sodium carbonate as an acid binder.
- a lower alkanol solvent illustratively ethanol
- an alkali metal salt as, for example, sodium carbonate as an acid binder.
- the reaction is preferably carried out at the reflux temperature of the solvent employed, and following the reaction period the product is extracted into an organic solvent, preferably ether, by acid-base extraction of the concentrated residue of the reaction mixture. After washing and drying, the solvent is evaporated and the product present in the residue is purified by conventional laboratory procedures as, for example, distillation, crystalllization, chromatography, and the like.
- EXAMPLE 1 3-benzoyl-l-ethylpyrrolidine
- An ethereal solution of phenylmagnesium bromide was prepared using 61 g. (2.5 mole) of magnesium, 41 0 g. (2.6 mole) of bromobenzene and 650 ml. of dry ether.
- the stirred ethereal solution was treated with 248 g. (2.0 mole) of B-cyano-l-ethylpyrrolidine dissolved in an equal volume of dry ether and following addition the mixture was refluxed six hours.
- the reaction mixture was decomposed by the careful addition of a solution of 250 g. of ammonium chloride in 750 ml. of water.
- 3-benzoyl-l-cyclohexylpyrrolidine is prepared from l-cyclohexyl-3-cyanopyrrolidine and phenylmagnesium bromide,
- 3-benzoyl-l-cyclopentylpyrrolidine is prepared from l-cyclopentyl-3-cyanopyrrolidine and phenylmagnesium bromide,
- cyclohexyl 3 (m tritiuoromethylbenzoyl) pyrrolidine is prepared from 1-cyclohexyl-3-cyanopyrrolidine and m-trifluoromethylphenylmagnesium bromide.
- the ketone was extracted with ether and the combined ether extracts were extracted with 6 N HCl.
- the acid extracts were made basic with 50% NaOH and the free base was taken up with ether.
- the ether extracts were washed with water and dried over magnesium sulfate. After the solvent was evaporated, the residual oil was distilled at reduced pressure and the fraction boiling at 98100 C./.003 mm. was collected. The light yellow, non-viscous oil weighed 120 g. (38% yield).
- To a warm solution of 3.7 g. (0.032 mole) of fumaric acid in 150 ml. of isopropanol was added 7.0 g. (0.032 mole) of the free base.
- the fumarate salt was collected and dried (8.5 g.; M.P. 122125 C.). After recrystallization from isopropanol the dried fumarate salt (5.0 g.) melted at 125-127 C.
- the ether layer was evaporated and the resulting aqueous suspension was heated for one hour on a steam bath to insure hydrolysis of the ketimine.
- the ketone was extracted with benzene and the combined extracts were extracted with 6 N HCl. After the acid extracts were made basic with 6 N NaOH, the free base was taken up in benzene. The benzene extracts were washed with water and dried over magnesium sulfate. After the solvent was evaporated, the residual oil was distilled at reduced pressure and the fraction boiling at l2ll24 C./ .07 mm. was collected. The light yellow, non-viscous oil weighed 30.8 g. (25% yield).
- the free base (12.0 g.; 0.044 mole) was added to a solution of 5.6 g. (0.044 mole) of oxalic acid dihydrate in hot isopropanol. The mixture was heated several minutes, filtered and cooled. The crystalline product which separated melted at 14l142 C. and weighed 12.2 g.
- the resulting suspension was stirred and heated on a stream bath for 16 hours, cooled and treated with 500 g. of 50% NaOH. Toluene was added to the flask and the mixture was heated for one hour on a steam bath to insure hydrolysis of the ketimine. The suspension was filtered and the cake washed with toluene. The organic layer was separated, washed with water and dried over magnesium sulfate. The solvent was evaporated and the residual oil was distilled at reduced pressure. The fraction boiling at 169-170 C./.05 mm. weighed 103 g. (41% yield). A portion of the free base (7.6 g.) was dissolved in isopropyl ether and treatedwith ethereal hydrogen chloride. The salt weighed 5.3 g. and melted at 163165 C. after it was recrystallized from an isopropanol-isopropyl ether mixture.
- the chloroform was evaporated and the residual oil which crystallize-d on cooling was recrystallized from ethyl acetate using charcoal.
- the product weighed 57 g. (58% yield). The material melted at 127.5128.5 C. after it was recrystallized from the ethyl acetate.
- the aqueous layer was made basic with NaOH and then extracted with chloroform.
- the chloroform was evaporated in the residual oil crystallized on cooling.
- the crystalline product weighed 32 g. (41% yield) after it was triturated with ethyl acetate and dried. The product was recrystallized from ethyl acetate-ethanol and the white crystalline material melted at 136.5137.5 C.
- the cooled acidic solution was decanted from a dark viscous residue and made basic with 25% sodium hydroxide and the basic solution extracted with benzene. The combined extracts were washed with water, dried over magnesium sulfate and the solvent evaporated.
- a solution of the residual oil (24 g., 0.1 mole) in isopropyl ether was treated with a solution of 12.6 g. (0.10 mole) of oxalic acid dihydrate in methanol.
- the crude salt which formed was recrystallized from isopropanol yielding 7.0 g. (7% yield) of product melting at 86-87 C.
- EXAMPLE 13 3- (p-fiuorobenzoyl -pyrrolidine oxalate) A mixture of 50 g. of 1-carbamoyl-3-(p-fluorobenzoyl)-pyrrolidine in 400 ml. of cone. HCl was refluxed three days, cooled and made basic with 50% NaOH. The oil which separated was extracted with benzene and the combined extracts were washed with water, dried over magnesium sulfate and the solvent evaporated. The residual oil weighed 19.0 g. (46% yield). A portion (1.9 g., 0.01 mole) of the free base was dissolved in isopropanol and treated with 1.3 g.
- EXAMPLE 14 1- [3-(p-acetyl-o-methoxyphenoxy propyl] -3- (p-fluorobenzoyl)-pyrrolidine oxalate
- EXAMPLE 16 1-[3-(p-acetyl-o-methoxyphenoxy)propyl]-3- benzoylpyrrolidine oxalate
- the organic layer was sep arated, washed with cold water and the solvent evaporated.
- the residual oil was dissolved in benzene and chromatographed on 150 g.
- EXAMPLE 18 fl-Aziridinylpropiophenone A solution of 35.4 gms. (0.20 mole) of B-dimethylaminopropiophenone in 200 ml. of dimethylformamide was treated with 50 gms. (1.16 mole) of aziridine and the reaction mixture was allowed to stand 48 hours at room temperature while a slow stream of nitrogen was passed through the mixture. The solution was poured into water and the aqueous solution extracted with benzene. The combined benzene extracts were washed with water and dried over magnesium sulfate. An aliquot of the benzene solution was concentrated and the residue 10 molecularly distilled at C./0.1 mm. The nuclear magnetic resonance spectrum was consistent with the proposed structure.
- EXAMPLE 19 l-carbethoxy-3-benzoylpyrrolidine (Method A) A solution containing approximately 0.20 mole of B- aziridinylpropiophenone in 200 ml. of dry benzene was treated dropwise at 20 C. with 18 gms. (0.17 mole) of ethylchlorocarbonate to give an almost quantitative yield of ,8 [N carbethoxy N (2 chloroethylamino)]- propiophenone. The course of the preceding reaction was followed by thin layer chromatography.
- EXAMPLE 20 1-carbethoxy-3-benzoylpyrrolidine (Method B) To a cold stirred mixture (0 C.) of 1.5 gms. (0.008 mole) of S-benzoylpyrrolidine, 2.2 gms. (0.016 mole) of potassium carbonate and 20 ml. of methylene chloride was added 0.88 gm. (0.008 mole) of ethyl chlorocarbonate. Approximately 10 gms. of ice was added to the reaction mixture which was stirred until the pot temperature reached room temperature. The two phase system was separated and the organic layer was washed with dilute hydrochloric acid, dried over magnesium sulfate and the dried oragnic solution concentrated to an oil. The oil was purified by chromatography using magnesium silicate, the pure product eluted from the column using benzene-acetone. The pure product weighed 1.0 gm. (50%). The material was molecularly distilled.
- the present invention also contemplates novel compositions containing the compounds of the invention as active ingredients.
- the active ingredient is incorporated in a suitable carrier, illustratively, a pharmaceutical carrier.
- suitable pharmaceutical carriers which are useful in formulating the compositions of this invention include starch, gelatin, glucose, magnesium, carbonate, lactose, malt and the like.
- Liquid compositions are also within the purview of this invention and suitable liquid pharmaceutical carriers include ethyl alcohol, water, saline, propylene glycol, glycerine, glucose syrup and the like.
- the physical form of the novel compositions depends in part upon the physical characteristics of the active ingredient.
- the composition is preferably formulated as a capsule or tablet.
- the composition is preferably formulated as a soft gelatin capsule.
- the preferred composition is a tablet containing the active ingredient in the form of its nontoxic acid-addition salt.
- compositions formed in accordance with this invention are listed:
- Typical blend for encapsulation Per capsule, mg. Active ingredient, as salt 5.0 Lactose 296.7 Starch 129.0
- Additional capsule formulations preferably contain a higher dosage of active ingredient and are as follows:
- a typical formulation for a tablet containing 5.0 mg. of active ingredient per tablet follows.
- the formulation may be used for other strengths of active ingredient by adjustment of weight of dicalcium phosphate.
- This blend is granulated using water as a granulating medium.
- the wet granules are passed through an eight mesh screen and dried at 140 to 160 degrees Fahrenheit over night.
- the dried 12 granules are passed through a number ten mesh screen and blended with the proper amount of calcium stearate and this blend is then converted into tablets on a suitable tablet press.
- B. mg. tablet Ingredients: Per tablet, mg. Active ingredient, as salt 100.0 Lactose 190.0 Dicalcium phosphate 72.2 Starch 54.0 Milo starch 21.6 Calcium stearate 2.2
- R is selected from the group consisting of hydrogen
- lower alkyl phenyllower alkyl, p-acetyl-o-methoxyphenoxyethyl, p-acetyl-o-methoxyphenoxypropyl, pfluorobenzoyl, lower cycloalkyl having three to nine carbon atoms inclusive, 2-ethoxyethyl,
- R is selected from the group consisting of hydrogen, lower alkoxy, trifluoromethyl, halogen having an atomic weight less than 80 and lower alkyl, and acid addition salts thereof.
- a compound of claim 1 which is 3-benzoyl-l-ethylpyrrolidine.
- a compound of claim 1 which is 3-benzoyl-1-methylpyrrolidine.
- a compound of claim 1 which is 3-benzoyl-1-isopropylpyrrolidine.
- a compound of claim 1 which is 3-benzoylpyrrol- 5 ALEX M AZEL Primary Examiner idine.
- a compound of claim 1 which is 3-(p-fiuoroben- TOVAR Asslstant Exammer zoyl)-pyrrolidine.
- a compound of claim 1 which is 3-(m-trifluoromethyl-benzoyl)-pyrro1idine. 1O 260326.3; 424274
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
United States Patent 3,489,769 1-SUBSTlTUTED-3AROYL-PYRROLIDINES Grover Cleveland Helsley and William John Welstead,
Jr., Richmond, Va., assignors to A. H. Robins Company, Incorporated, Richmond, Va., a corporation of Virginia No Drawing. Continuation-impart of application Ser. No. 570,722, Aug. 8, 1966. This application June 20, 1968, Ser. No. 738,414
Int. Cl. C07d 27/06 US. Cl. 260-326.5 16 Claims ABSTRACT OF THE DISCLOSURE The present invention describes l-substituted 3-aroylpyrrolidines which have been shown to be useful in lowering plasma cholesterol levels. The compounds are prepared from l-substituted-3cyanopyrrolidines by reaction with aryl magnesium halides.
Formula I wherein:
R is hydrogen, lower alkyl, aryllower-alkyl, aryloxy,
ethoxy, aroyl, lower cycloalkyl, carbethoxy, and w-alkoxyalkyl,
R is hydrogen, lower alkoxy, trifluoromethyl, halogen having an atomic weight less than 80, and lower alkyl, and acid addition salts thereof.
The compounds of the invention having the foregoing Formula I are generally characterized by important pharmacological activity and are eifective as hypocholesterolemic agents and, as such, are particularly useful in lowering plasma cholesterol levels in living animal bodies as demonstrated in rats. Male rats of the Sprague-Dawley strain, weighing between 150200 grams, were placed in individual cages with raised wire floors and subjected to a 12-hour day with artificial lighting in a room controlled at 7578 F. The rats remained under these conditions for four days prior to experimentation to adjust to their environment. They were fed a semi-purified basal diet containing 0.375% by weight of the compound being investigated. On the fifth day the rats were randomly selected and divided into two groups. At the end of 21 days and after an overnight fast, the rats were anesthetized with ether and terminally bled from the dorsal aorta into heparinized tubes (Proc. Animal Care Panel 11, 305, 1961). Plasma was extracted according to Dole and Meinertz (J. Biol. Chem. 235, 2995, 1960), and lipids were resolved on a silicic acid column (I. Am. Oil. Chem. Soc. 36, 294, 1959) and total cholesterol (Am. J. Clin. Path. 27, 583, 1957) was analyzed (Clin. Chem. 7, 249, 1961). Among the novel compounds of the present invention the preferred compound is Example No. 5, 1-(2- ethoxyethyl)3-(4-fluorobenzoyl)pyrrolidine. When test- 3,489,769 Patented Jan. 13, 1970 ed as described hereinabove, the plasma cholesterol level in rats was lowered approximately 50%. The 50% lowering of plasma chloresterol is comparable to that obtained when the known cholesterol lowering agent, ethyl 2-(pchlorophenoxy)2-methylpropionate (Atromid-S was used as a control drug in the procedure described hereinabove.
It is, accordingly, an object of the present invention to provide new and useful l-substituted-3-aroyl pyrrolidines and methods of making the same. Other objects of the invention will be apparent to one skilled in the art, and still others will become apparent hereinafter.
In the definition of the symbols in the foregoing Formula I and where they appear elsewhere throughout this specification the terms have the following significance.
The term lower alkyl as used herein includes straight and branched chain radicals of up to eight carbon atoms inclusive, preferably no more than six carbon atoms, and is exemplified by such groups as methyl, ethyl, propyl, isopropyl, butyl, sec. butyl, tertiary butyl, amyl, isoamyl, hexyl, heptyl, octyl and the like. A lower-alkoxy group has the formula O-lower-alkyl.
The term lower cycloalkyl as used herein includes primarily cyclic radicals containing three up to nine carbon atoms inclusive and encompasses such groups as cyclopropyl, cyclobutyl, cyclohexyl, cyclopentyl, methylcyclohexyl, propylcyclohexyl, ethylcyclopentyl, propylcyclopentyl, dimethylcyclohexyl, cycloheptyl, and cyclooctyl.
The term lower alkylene has the formula (CH wherein m is a positive integer from l-4 inclusive.
Included in the term aryllower-alkyl are lower-alkyl substituted phenyl groups such as benzyl, phenethyl, methylbenzyl, phenpropyl and the like.
An aryl radical refers to the. phenyl radical alone or to a phenyl radical substituted by any radical or radicals which are not reactive or otherwise interfering under the conditions of reaction, such radicals including lower alkoxy, lower alkyl, trifiuoromethyl, halo and the like. The aryl radicals have preferably no more than one to three substituents such as those given above and, furthermore, these substituents can be in various available positions of the aryl nucleus and, when more than one substituent is present, can be the same or different and can be in various position combinations relative to each other.
An aroyl radical has the formula An aryloxy radical has the formula O-aryl.
This invention also includes acid addition salts of the above defined bases formed with nontoxic organic and inorganic acids. Such salts are easily prepared by methods known in the art. When the compounds are to be used as intermediates for preparing other compounds or for any other non-pharmaceutical use, the toxicity or nontoxicity of the salt is immaterial; when the compounds are to be used as pharmaceuticals, they are most conveniently used in the form of nontoxic acid-addition salts. Both toxic and nontoxic salts are therefore within the purview of the invention. The acids which can 'be used to prepare the preferred nontoxic acid-addition salts are those which produce, when combined with the free bases, salts whose anions are relatively innocuous to the animal organism in therapeutic doses of the salts, so that beneficial physiological properties inherent in the free bases are not vitiated by side effects ascribable to the anions.
The base is reacted with the calculated amount of organic or inorganic acid in aqueous miscible solvent, such as ethanol or isopropanol, with isolation of the salt by concentration and cooling, or the base is reacted with an excess of the acid in aqueous immiscible solvent, such as ethyl ether or isopropyl ether, with the desired salt separating directly. Exemplary of such organic salts are those formed with maleicQ-fumaric, benzoic, ascorbic, pamoic, succinic, methanesulfonic, acetic, propionic, tartaric, citric, lactic, malic, citraconic, itaconic, hexamic, p-arninobenzoic, glutamic, stearic acid and the like. Exemplary of such inorganic salts are those formed with hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric and nitric acids.
The novel compounds of this invention as represented by Formula I are prepared from 1-R-3-cyanopyrrolidines prepared as described in US. Patent 3,318,908. Thus a l-R-3-cyanopyrrolidine of Formula II, wherein R is lower alkyl, lower cycloalkyl, aryl and phenyllower-alkyl is reacted in a dry inert organic solvent, preferably ether, with an arylmagnesium halide to give a 1-R-3-aroylpyrrolidine of Formula III, wherein R is as defined immediately hereinabove.
Of particular value is the compound of Formula II, wherein R is phenylloWer-alkyl as represented by the benzyl group. The 1-benzyl-3-aroylpyrrolidine of Formula III prepared from 1-benzyl-3-cyanopyrrolidine and an arylmagnesium halide is reacted with an excess of cyanogen bromide in a dry inert organic solvent, illustratively chloroform, to give a 1-cyano-3-aroylpyrrolidine which generally is not isolated, and is hydrolyzed with dilute hydrochloric acid for a period of from about 12 hours to about 16 hours to give a 1-carbamoyl-3-aroylpyrrolidine. The latter compound is further hydrolyzed with concentrated hydrochloric acid for a periodof from 48 hours to about 72 hours to give a 3-aroylpyrrolidine. Alternately, the residual crude material remaining after evaporation of the chloroform solvent following the reaction described above with cyanogen bromide can be hydrolyzed directly to the 3-aroylpyrrolidine using concentrated hydrochloric acid.
3-aroylpyrrolidines can also be prepared by another method as follows:
(1) An w-dialkylamino propionphenone is reacted with aziridine, the aziridine moiety displacing the dialkylamino group to give an w-aziridinylpropiophenone of Formula IV.
(2) The w-aziridinylpropiophenone of Formula IV is treated in a dry inert solvent below 20 C. with ethyl chlorocarbonate to give an w-[N-carbethoxy-N-(Z-chloroethyl)amino]-propiophenone of Formula V.
H2 Formula IV COOC H CHgCHzCl Formula V C 0 00 115 Formula VI (4) The 1-carbethoxy-3-aroylpyrrolidine of Formula VI is hydrolyzed under acidic conditions to a 3-aroylpyrrolidine.
The 3-aroylpyrrolidines prepared by the methods described hereinabove constitute novel compounds of Formula I which are especially useful in preparing other novel and useful compounds within the scope of Formula I. Thus, the hydrogen atom of the secondary amine group of the pyrrolidine nucleus exhibits all the reactive properties of a secondary amino group and enters readily into conventional displacement reactions with a variety of reactive compounds, including, for example, alkyl halides, aralkyl halides, N-mono and N,N-disubstituted carbamoyl halides, arylsulfonyl halides, and the like.
Generally speaking, the 3-aroylpyrrolidines prepared as described above are reacted with compounds containing reactive halogen atoms in a lower alkanol solvent, illustratively ethanol, containing an alkali metal salt as, for example, sodium carbonate as an acid binder. The reaction is preferably carried out at the reflux temperature of the solvent employed, and following the reaction period the product is extracted into an organic solvent, preferably ether, by acid-base extraction of the concentrated residue of the reaction mixture. After washing and drying, the solvent is evaporated and the product present in the residue is purified by conventional laboratory procedures as, for example, distillation, crystalllization, chromatography, and the like.
For specific insight into the type of reactions involved, the intermediates therefor and the manner of carrying them out, and the novel compounds, some of these are specifically set forth in a series of specific examples which follow. It is to be understood the examples are given by way of illustration only and are not to be construed as limiting.
EXAMPLE 1 3-benzoyl-l-ethylpyrrolidine An ethereal solution of phenylmagnesium bromide was prepared using 61 g. (2.5 mole) of magnesium, 41 0 g. (2.6 mole) of bromobenzene and 650 ml. of dry ether. The stirred ethereal solution was treated with 248 g. (2.0 mole) of B-cyano-l-ethylpyrrolidine dissolved in an equal volume of dry ether and following addition the mixture was refluxed six hours. The reaction mixture was decomposed by the careful addition of a solution of 250 g. of ammonium chloride in 750 ml. of water. Following evaporation of the ether, the solution was heated on the steam bath to complete hydrolysis of the ketimine. The product was extracted with ether and then separated from nonbasic materials by acid-base extraction. The residual oil was distilled at 97-99 C./.05 mm. to give 180 g. (44%) of 3-benzoyl-l-ethylpyrrolidine.
Using the process given above in Example 1, the following compounds are prepared from the stated ingredients:
3-benzoyl-l-cyclohexylpyrrolidine is prepared from l-cyclohexyl-3-cyanopyrrolidine and phenylmagnesium bromide,
3-benzoyl-l-cyclopentylpyrrolidine is prepared from l-cyclopentyl-3-cyanopyrrolidine and phenylmagnesium bromide,
1 cyclohexyl 3 (m tritiuoromethylbenzoyl) pyrrolidine is prepared from 1-cyclohexyl-3-cyanopyrrolidine and m-trifluoromethylphenylmagnesium bromide.
EXAMPLE 2 3-benzoyl-1-rnethylpyrrolidine To a stirred ether solution of phenylmagnesium bromide prepared from 37.5 g. (1.55 mole) of magnesium, 251 g. (1.60 mole) of bromobenzene and 425 ml. of dry ether was added dropwise a solution of g. (1.27 mole) of 3-cyano-l-methylpyrrolidine in 200 ml. of dry ether. After refluxing two hours, the cooled reaction mixture was treated with a solution of 80 g. of ammonium chloride in 260 ml. of water. The ether was evaporated, the aqueous solution heated one hour to complete hydrolysis of the ketimine and the ketone product extracted with ether. Non-basic materials were separated by acid-base extraction. The residual oil after removal of the ether solvent was distilled in vacuo to give 102 g. (41%) of product at 93-95 C./.05 mm.
Analysis.Calculated for C H NO: N, 7.40. Found: N, 7.57.
EXAMPLE 3 3-benzoyl-l-isopropylpyrrolidine fumarate To a stirred solution of 2 moles of phenyl magnesium bromide in one liter of ether was added slowly 202 g. (1.46 mole) of 3-cyano-l-isopropylpyrrolidine in 200 ml. of dry ether. After the addition was complete the mixture was stirred and refluxed for three hours and then allowed to stand overnight. To the cooled suspension was then added slowly with stirring 250 g. of ammonium chloride in 750 ml. of water. After the ether was evaporated, the mixture was heated for one hour on a steam bath to insure hydrolysis of ketimine. The ketone was extracted with ether and the combined ether extracts were extracted with 6 N HCl. The acid extracts were made basic with 50% NaOH and the free base was taken up with ether. The ether extracts were washed with water and dried over magnesium sulfate. After the solvent was evaporated, the residual oil was distilled at reduced pressure and the fraction boiling at 98100 C./.003 mm. was collected. The light yellow, non-viscous oil weighed 120 g. (38% yield). To a warm solution of 3.7 g. (0.032 mole) of fumaric acid in 150 ml. of isopropanol was added 7.0 g. (0.032 mole) of the free base. The fumarate salt was collected and dried (8.5 g.; M.P. 122125 C.). After recrystallization from isopropanol the dried fumarate salt (5.0 g.) melted at 125-127 C.
Analysis.-Calculated for C H NO C, 64.85; H, 6.95; N, 4.20. Found: C, 65.16; H, 6.96; N, 4.05.
EXAMPLE 4 1-methyl-3-(m-methoxybenzoyl)-pyrrolidine To a stirred Grignard solution prepared from 14.6 g. (0.60 mole) of magnesium, 112 g. (0.60 mole) of m-bromoanisole in 250 ml. of ether was added slowly at a rate which maintained gentle refluxing a solution of 60.5 g. (0.55 mole) of 1-methyl-3-cyanopyrrolidine in 50 ml. of dry ether. Stirring was continued for one hour after the addition was complete. To the cooled mixture was then added slowly a solution of 32 g. (0.60 mole) of ammonium chloride in 400 ml. of water. The ether layer was evaporated and the resulting aqueous suspension was heated for one hour on a steam bath to insure hydrolysis of the ketimine. The ketone was extracted with benzene and the combined extracts were extracted with 6 N HCl. After the acid extracts were made basic with 6 N NaOH, the free base was taken up in benzene. The benzene extracts were washed with water and dried over magnesium sulfate. After the solvent was evaporated, the residual oil was distilled at reduced pressure and the fraction boiling at l2ll24 C./ .07 mm. was collected. The light yellow, non-viscous oil weighed 30.8 g. (25% yield).
Analysis.Calculated for C H NO C, 71.20; H, 7.82; N, 6.39. Found: C, 70.60; H, 7.89; N, 6.41.
EXAMPLE 5 1- (2-ethoxyethyl) -3- (p-fluorobenzoyl -pyrrolidine oxalate To a stirred Grignard solution prepared from 11.2 g. (0.46 mole) of magnesium, 80.5 g. (0.46 mole) of pbrornofluorobenzene in 300 ml. of ether was added slowly at a rate which maintained gentle refluxing a solution of 44 g. (0.26 mole) of 1-(2-ethoxyethyl)-3-cyanopyrrolidine in 60 ml. of dry ether. Stirring was continued for one hour after the addition was complete. To the cooled mixture was added slowly a solution of 26.8 g. (0.50 mole) of ammonium chloride in 300 m1. of water. The ether layer was evaporated and the aqueous suspension heated for an hour on a steam bath to insure hydrolysis of the ketimine. The ketone was extracted with ether and the combined extracts were extracted with 6 N HCl. After the acid extracts were made basic with 6 N NaOH the free base which separated was taken up in ether. The ether extracts were washed with water and dried over magnesium sulfate. After the solvent was evaporated, the residual oil was distilled at reduced pressure and the fraction boiling at ISO-133 C./0.07 mm. was collected. The light yellow, non-viscous oil weighed 12.9 g. (19% yield). The free base (12.0 g.; 0.044 mole) was added to a solution of 5.6 g. (0.044 mole) of oxalic acid dihydrate in hot isopropanol. The mixture was heated several minutes, filtered and cooled. The crystalline product which separated melted at 14l142 C. and weighed 12.2 g.
EXAMPLE 6 1-benzyl-3-benzoylpyrrolidine hydrochloride hydrate To a stirred solution of 544 g. (3.0 mole) of phenylmagnesium bromide in 1.5 liters of dry ether was added 279 g. (1.5 mole) of 1-benzyl-3-cyanopyrrolidine in 400 ml. of dry ether at a rate which maintained gentle refluxing. The mixture was stirred for two hours at room temperature after the addition was complete, cooled and treated with 151 g. (3.0 mole) of ammonium chloride in 900 ml. of water. After the ether was evaporated the aqueous suspension was heated on a steam bath for several hours to insure hydrolysis of the ketimine. The mixture was then extracted with ether and the combined extracts were washed with water and dried over magnesium sulfate. The solvent was evaporated and the residual oil distilled at reduced pressure. The light yellow oil boiling at 172175 C./.08 mm. weighed 210 g. (53% yield). A portion of the free base (6 g.) was treated with 3 N HCl and the white crystalline hydrochloride which formed was recrystallized from water. The salt weighed 2.6 g. and melted at 116118.5 C.
Analysis.Calculated for C H NO Cl: C, 67.59; H, 6.93; N, 4.38. Found: C, 67.85; H, 6.94; N, 4.42.
EXAMPLE 7 1-benzyl-3 (m-trifluoromethylbenzoyl) -pyrrolidine hydrochloride To a stirred Grignard solution prepared from 32.4 g. (1.3 mole) of magnesium, 300 g. (1.3 mole) of m-bromobenzotrifluoride in 450 ml. of ether was added 186 g. (1.0 mole) of 1-benzyl-3-cyanopyrrolidine in 200 ml. of dry ether at a rate which maintained gentle refluxing. The mixture was stirred at reflux for one hour, cooled and treated with a solution of 70 g. (1.3 mole) of ammonium chloride in 600 ml. of water. After the ether was evaporated, the mixture was heated for one hour on a steam bath to insure hydrolysis of the ketimine. The mixture was extracted with ether and the combined extracts were washed with water, dried over magnesium sulfate and the solvent evaporated. The residual oil was distilled at reduced pressure and the fraction boiling at l67 C./.07 mm. collected. The light yellow oil weighed 123 g. (37% yield). A portion (23 g.) of the product was redistilled slowly and the fraction boiling at 148-150 C./.04 mm. collected. The oil weighed 16 g. A portion (10 g.) of the oil was dissolved in ether and treated with ethereal hydrogen chloride. The white hydrochloride which formed melted at 15 8160 C. and weighed 9.8 g. after it was recrystallized from methyl ethyl ketone.
Analysis.-Calculated for C H NOClF C, 61.70; H, 5.18; N, 3.79. Found: C, 61.75; H, 5.15; N, 3.99.
7 EXAMPLE 8 1-benzy1-3-(p-fluorobenzoyl)-pyrrolidine hydrochloride To the stirred Grignard solution prepared from 42.5 g. (1.76 mole) of magnesium, 308 g. (1.76 mole) of fluorobromobenzene in 700 ml. of ether was added 164 g. (0.88 mole) of 1-benzyl-3-cyanopyrrolidine in 100 ml. of dry ether at a rate which maintained gentle refluxing. The mixture was stirred for one hour at ambient temperature, cooled and treated with a solution of 94 g. (1.8 mole) of ammonium chloride in 500 ml. of water. The resulting suspension was stirred and heated on a stream bath for 16 hours, cooled and treated with 500 g. of 50% NaOH. Toluene was added to the flask and the mixture was heated for one hour on a steam bath to insure hydrolysis of the ketimine. The suspension was filtered and the cake washed with toluene. The organic layer was separated, washed with water and dried over magnesium sulfate. The solvent was evaporated and the residual oil was distilled at reduced pressure. The fraction boiling at 169-170 C./.05 mm. weighed 103 g. (41% yield). A portion of the free base (7.6 g.) was dissolved in isopropyl ether and treatedwith ethereal hydrogen chloride. The salt weighed 5.3 g. and melted at 163165 C. after it was recrystallized from an isopropanol-isopropyl ether mixture.
Analysis.Calculated for C H ClFNO: C, 67.60; H, 5.99; N, 4.38. Found: C, 67.82; H, 5.95; N, 4.54.
EXAMPLE 9 3-benzoyl-l-carbamoylpyrrolidine To a stirred solution of 68.8 g. (0.65 mole) of cyanogen bromide in one liter of chloroform was added 148 g. (0.56 mole) of l-benzyl-3-benzoylpyrrolidine in 200 ml. of chloroform over a period of five hours. After the addition was complete, the solution was refluxed for one hour and then the solvent was evaporated at reduced pressure. The residual oil was treated with 1600 ml. of 4 N HCl and refluxed for 16 hours. The mixture was cooled and extracted with ether. The aqueous layer was treated with NaOH and then extracted with chloroform. The chloroform was evaporated and the residual oil which crystallize-d on cooling was recrystallized from ethyl acetate using charcoal. The product weighed 57 g. (58% yield). The material melted at 127.5128.5 C. after it was recrystallized from the ethyl acetate.
Analysis.Calculated for C H N O C, 66.03; H, 6.46; N, 12.83. Found: C, 65.83; H, 6. 48; N, 12.71.
EXAMPLE 1-carbamoyl-3 (p-fluo robenzoyl -pyrrolidine To a stirred solution of 44.6 g. (0.43 mole) of cyanogen bromide in 400 ml. of chloroform was added 95 g. (0.33 mole) of 1-benzyl-3-(p-fluorobenzoyl)-pyrrolidine in 100 ml. of chloroform over a period of five hours. After the addition was complete, the solution was refluxed for 1.5 hours and then the solvent was evaporated at reduced pressure. The residual oil was treated with 1600 ml. of 4 N HCl and refluxed for 16 hours. The mixture was cooled and extracted with ether. The aqueous layer was made basic with NaOH and then extracted with chloroform. The chloroform was evaporated in the residual oil crystallized on cooling. The crystalline product weighed 32 g. (41% yield) after it was triturated with ethyl acetate and dried. The product was recrystallized from ethyl acetate-ethanol and the white crystalline material melted at 136.5137.5 C.
Analysis.Calculated for C H FN O C, 61.01; H, 5.54; N, 11.86. Found: C, 61.09; H, 5.41; N, 11.61.
EXAMPLE l1 3-(m-trifluoromethylbenzoyl)-pyrrolidine oxalate To a stirred solution of 44.6 g. (0.043 mole) of cyanogen bromide in 400 ml. of chloroform was added over a period of four hours, 102 g. (0.31 mole) of 1-benzyl-3 (rn-trifiuoromethylbenzoyl)-pyrrolidine. After the addition was complete, the mixture was heated at reflux for one hour and then the solvent was evaporated at reduced pressure. An acidic solution of the residual oil in 1200 ml. of 3 N hydrochloric acid was refluxed for 24 hours. The cooled acidic solution was decanted from a dark viscous residue and made basic with 25% sodium hydroxide and the basic solution extracted with benzene. The combined extracts were washed with water, dried over magnesium sulfate and the solvent evaporated. A solution of the residual oil (24 g., 0.1 mole) in isopropyl ether was treated with a solution of 12.6 g. (0.10 mole) of oxalic acid dihydrate in methanol. The crude salt which formed was recrystallized from isopropanol yielding 7.0 g. (7% yield) of product melting at 86-87 C.
Analysis.Calculated for C H F NO C, 50.45; H, 4.23; N, 4.20. Found: C, 50.33; H, 4.29; N, 4.47.
EXAMPLE l2 3-benzoylpyrrolidine hydrochloride hydrate A solution of 18 g. of 3-benzoyl-l-carbamoylpyrrolidine in 120 ml. of concentrated HCl was refluxed three days, cooled and made basic with 50% NaOH. The oil which separated was extracted with benzene and the combined extracts were washed with water, dried over magnesium sulfate and the solvent evaporated. The residual oil weighed 8.1 g. (53% yield). A portion of the free base (5.0 g.) was dissolved in isopropanol and treated with ethereal HCl. The salt which formed was recrystallized from an isopropanol-ether mixture. The product weighed 2.5 g. and melted at 5961 C.
Analysis.--Calculated for C H NO CI: C, 57.51; H, 7.02; N, 6.10. Found: C, 57.73; H, 6.80; N, 6.22.
EXAMPLE 13 3- (p-fiuorobenzoyl -pyrrolidine oxalate A mixture of 50 g. of 1-carbamoyl-3-(p-fluorobenzoyl)-pyrrolidine in 400 ml. of cone. HCl was refluxed three days, cooled and made basic with 50% NaOH. The oil which separated was extracted with benzene and the combined extracts were washed with water, dried over magnesium sulfate and the solvent evaporated. The residual oil weighed 19.0 g. (46% yield). A portion (1.9 g., 0.01 mole) of the free base was dissolved in isopropanol and treated with 1.3 g. (0.01 mole) of oxalic acid dihydrate and heated several minutes. The crystalline salt which separated on cooling was recrystallized again from the same solvent. The salt weighed 1.8 g. and melted at 116119 C. (rapid heating). When the salt was heated slowly it softened at 115-117 C. and melted at 120- 124 C.
AnaZysis.-Calculated for C H FNO C, 55.12; H, 4.98; N, 4.95. Found: C, 55.40; H, 5.01; N, 4.99.
EXAMPLE 14 1- [3-(p-acetyl-o-methoxyphenoxy propyl] -3- (p-fluorobenzoyl)-pyrrolidine oxalate A stirred mixture of 4.8 g. (0.025 mole) of 3-(p fluorobenzoyl)-pyrrolidine, 7.8 g. (0.027 mole) of 3-(pacetyl-o-methoxyphenoxy)-propyl bromide, 14 g. of potassium carbonate and 100 ml. of l-butanol was heated at -80 C. for 16 hours, cooled, filtered and the solvent evaporated. The residual oil was taken up in benzene and washed with water. After the solution was dried over magnesium sulfate, the solvent was evaporated. The residual oil was dissolved in isopropanol and treated with 3.2 g. (0.025 mole) of oxalic acid dihydrate, heated for several minutes and the resulting solution filtered. The salt which crystallized on cooling weighed 7.1 g. (61% yield) and melted at -103 C.
Analysis.Calculated for C H FNO C, 61.34; H, 5.77; N, 2.86. Found: C, 61.86; H, 5.79; N, 2.86.
9 EXAMPLE 1-[2-(p-acetyl-o-methoxyphenoxy) -ethyl] -3- benzoylpyrrolidine oxalate A stirred mixture of 3.5 g. (0.02 mole) of 3-benzoy1- pyrrolidine, 5.5 g. (0.02 mole) Z-(p-acetyl-o-methoxyphenoxy)-ethyl bromide, 12 g. of potassium carbonate and 75 ml. of l-butanol was heated at 75-78 C. -for 16 hours, cooled, filtered and the solvent evaporated. The residual oil was dissolved in benzene and chromatographed on 200 g. of 60-100 mesh magnesium silicate, eluting which a benzene-acetone mixture. The product Weighed 4.1 g. (56% yield). The free base was dissolved in isopropanol and treated with 2.5 g. (0.02 mole) of oxalic acid dihydrate. The crystalline salt which formed was recrystallized twice from isopropanol. The product weighing 3.4 g. softened at 127 C. and melted at 129- 132 C.
Analysis.Calculated for C24H27NO3: C, 63.01; H, 5.95; N, 3.06. Found: C, 63.01; H, 6.06; N, 3.14.
EXAMPLE 16 1-[3-(p-acetyl-o-methoxyphenoxy)propyl]-3- benzoylpyrrolidine oxalate A mixture of 3.5 g. (0.02 mole) of 3-benzoylpyrrolidine, 5.7 g. (0.02 mole) of 3-(p-acetyl-o-methoxyphenoxy)-propyl bromide, 12 g. of potassium carbonate and 75 ml. of toluene was refluxed for 16 hours, cooled and treated with 100 ml. of water. The organic layer was sep arated, washed with cold water and the solvent evaporated. The residual oil was dissolved in benzene and chromatographed on 150 g. of magnesium silicate, eluting with a benzene-acetone mixture. The product weighed 2.0 g. (26% yield). The free base was treated with a solution of 0.7 g. (0.06 mole) of oxalic acid in isopropanol. The salt which separated weighed 2.2 g. and melted at 114-119 C.
Analysis.Calculated for C H NO C, 63.68; H, 6.20; N, 2.97. Found: C, 63.47; H, 6.13; N, 3.05.
EXAMPLE 17 1- 3- (p-fluorobenzoyl) -propyl] -3-(p-fluoro- =benzoyl)-pyrrolidine A stirred mixture of 3.8 g. (0.020 mole) of 3-(pfluorobenzoyl)-pyrrolidine, 5.8 g. (0.024 mole) of 2-(3- chloropropyl)-2-(p-fluorophenyl)-l,3-dioxolane, 14.0 g.
of potassium carbonate and 75 m1. of l-butanol was heated at 80 C. for 32 hours and then at reflux for 16 hours. The cooled suspension was filtered and the solvent evaporated at reduced pressure. The residual oil was stirred in a mixture of 100 ml. of 3 N HCl and 100 ml. of ethanol for one hour. After the mixture was made basic with 50% NaOH, the oil in which separated was extracted with benzene and the benzene evaporated. The residual oil (6.1 g.) was chromatographed on 200 g. of 60-100 mesh magnesium silicate, eluting with a benzene-acetone mixture. The product (tan wax) weighed 1.5 g. (21% yield). A portion of the product was molecularly distilled to obtain a pure sample.
Analysis.Calculated for C21H21F2NO21 C, H, 5.92; N, 3.92. Found: C, 70.81; H, 6.10; N, 3.98.
EXAMPLE 18 fl-Aziridinylpropiophenone A solution of 35.4 gms. (0.20 mole) of B-dimethylaminopropiophenone in 200 ml. of dimethylformamide was treated with 50 gms. (1.16 mole) of aziridine and the reaction mixture was allowed to stand 48 hours at room temperature while a slow stream of nitrogen was passed through the mixture. The solution was poured into water and the aqueous solution extracted with benzene. The combined benzene extracts were washed with water and dried over magnesium sulfate. An aliquot of the benzene solution was concentrated and the residue 10 molecularly distilled at C./0.1 mm. The nuclear magnetic resonance spectrum was consistent with the proposed structure.
EXAMPLE 19 l-carbethoxy-3-benzoylpyrrolidine (Method A) A solution containing approximately 0.20 mole of B- aziridinylpropiophenone in 200 ml. of dry benzene was treated dropwise at 20 C. with 18 gms. (0.17 mole) of ethylchlorocarbonate to give an almost quantitative yield of ,8 [N carbethoxy N (2 chloroethylamino)]- propiophenone. The course of the preceding reaction was followed by thin layer chromatography.
The benzene solution of S-[N-carbethoxy-N-(2-chloroethylamino)l-propiophenone was treated with 4.8 gms. (0.20 mole) of sodium hydride. No reaction occurred when the benzene solution was refluxed. Dimethylformamide was added to the benzene solution resulting in a vigorous evolution of hydrogen gas. The solution after refluxing for a short period was cooled, poured into water, the benzene layer separated, dried over magnesium sulfate and concentrated to an oil. The oil was chromatographed on 800 gms. of 60100 mesh magnesium silicate and the product eluted from the column using benzene-acetone solution. The infrared and nuclear magnetic spectra of the product was identical to that of l-carbethoxy-3-benzoylpyrrolidine prepared by Method B described in Example 20.
EXAMPLE 20 1-carbethoxy-3-benzoylpyrrolidine (Method B) To a cold stirred mixture (0 C.) of 1.5 gms. (0.008 mole) of S-benzoylpyrrolidine, 2.2 gms. (0.016 mole) of potassium carbonate and 20 ml. of methylene chloride was added 0.88 gm. (0.008 mole) of ethyl chlorocarbonate. Approximately 10 gms. of ice was added to the reaction mixture which was stirred until the pot temperature reached room temperature. The two phase system was separated and the organic layer was washed with dilute hydrochloric acid, dried over magnesium sulfate and the dried oragnic solution concentrated to an oil. The oil was purified by chromatography using magnesium silicate, the pure product eluted from the column using benzene-acetone. The pure product weighed 1.0 gm. (50%). The material was molecularly distilled.
Analysis.Calculated for C14H17NO3Z C, 68.00; H, 6.93; N, 5.67. Found: C, 67.93; H, 6.99; N, 5.84.
EXAMPLE 21 3-benzoylpyrrolidine hydrochloride hydrate Ten grams (0.04 mole) of 3-benzoyl-1-carbethoxypyrrolidine was mixed with 25 ml. of absolute ethanol and 25 ml. of concentrated hydrochloric acid and the solution refluxed for 18 hours. The cooled reaction mixture was extracted with ether and the aqueous acid solution was concentrated to an oil. The oil was dissolved in hot acetone and from the cooled acetone solution 5.0 gms. (63%) of the hydrochloride salt was obtained. The salt melted at 59-61%. A mixture melting point with the compound prepared in Example 12 showed no depression.
The present invention also contemplates novel compositions containing the compounds of the invention as active ingredients. In forming the novel compositions of this invention, the active ingredient is incorporated in a suitable carrier, illustratively, a pharmaceutical carrier. Suitable pharmaceutical carriers which are useful in formulating the compositions of this invention include starch, gelatin, glucose, magnesium, carbonate, lactose, malt and the like. Liquid compositions are also within the purview of this invention and suitable liquid pharmaceutical carriers include ethyl alcohol, water, saline, propylene glycol, glycerine, glucose syrup and the like. The physical form of the novel compositions depends in part upon the physical characteristics of the active ingredient. When the active ingredient is a solid, the composition is preferably formulated as a capsule or tablet. When the active ingredient is a liquid, the composition is preferably formulated as a soft gelatin capsule. The preferred composition is a tablet containing the active ingredient in the form of its nontoxic acid-addition salt.
The following are examples of compositions formed in accordance with this invention:
(1) CAPSULES Capsules of 5 mg., 25 mg., and 50 mg. of active ingredient per capsule are prepared. With the higher amounts of active ingredient, reduction may be made in the amount of lactose.
Typical blend for encapsulation: Per capsule, mg. Active ingredient, as salt 5.0 Lactose 296.7 Starch 129.0
Magnesium stearate 4.3
Total 435.0
Additional capsule formulations preferably contain a higher dosage of active ingredient and are as follows:
100 mg. per 250 mg. per 500 mg. per
Ingredients capsule capsule capsule Active ingredient, as salt- 100. 250. 0 500.0 Lactose 231. 126. 5 31. 1 Starch 99. 2 54. 2 13. 4 Magnesium stearate. 4. 3 4. 3 5. 5
Total 435. 0 435. 0 550. 0
In each case, uniformly blend the selected active ingredient with lactose, starch, and magnesium stearate and encapsulate the blend.
2 TABLETS A typical formulation for a tablet containing 5.0 mg. of active ingredient per tablet follows. The formulation may be used for other strengths of active ingredient by adjustment of weight of dicalcium phosphate.
Per tablet, mg.
(1) Active ingredient, as salt 5.0 (2) Corn starch 13.6 (3) Corn starch (paste) 3.4 (4) Lactose 79.2 (5) Dicalcium phosphate 68.0 (6) Calcium stearate 0.9
Total 170.1
A. 50 mg. tablet Ingredients: Per tablet, mg. Active ingredient, as salt 50.0 Lactose 90.0
Milo starch 20.0 Corn starch 38.0 Calcium stearate 2.0
Total 200.0
Uniformly blend the active ingredient, lactose, milo starch and the corn starch. This blend is granulated using water as a granulating medium. The wet granules are passed through an eight mesh screen and dried at 140 to 160 degrees Fahrenheit over night. The dried 12 granules are passed through a number ten mesh screen and blended with the proper amount of calcium stearate and this blend is then converted into tablets on a suitable tablet press.
B. mg. tablet Ingredients: Per tablet, mg. Active ingredient, as salt 100.0 Lactose 190.0 Dicalcium phosphate 72.2 Starch 54.0 Milo starch 21.6 Calcium stearate 2.2
Total 540.0
Uniformly blend the active ingredient, lactose, dicalcium phosphate, starch and milo starch. This blend is granulated with water and the wet mass is passed through a number eight mesh screen. The wet granules are dried at -160 degrees Fahrenheit over night. The dried granules are passed through a number ten mesh screen. These dried granules are blended with the proper weight of calcium stearate and the lubricated granules are then converted into tablets on a suitable tablet press.
Various modifications and equivalents will be apparent to one skilled in the art and may be made in the compounds, compositions, methods, and procedures of the present invention without departing from the spirit or scope thereof, and it is therefore to be understood that the invention is to be limited only by the scope of the appended claims.
What is claimed:
1. A compound selected from the group having the formula:
wherein;
R is selected from the group consisting of hydrogen,
lower alkyl, phenyllower alkyl, p-acetyl-o-methoxyphenoxyethyl, p-acetyl-o-methoxyphenoxypropyl, pfluorobenzoyl, lower cycloalkyl having three to nine carbon atoms inclusive, 2-ethoxyethyl,
R is selected from the group consisting of hydrogen, lower alkoxy, trifluoromethyl, halogen having an atomic weight less than 80 and lower alkyl, and acid addition salts thereof.
2. A compound of claim 1 which is 3-benzoyl-l-ethylpyrrolidine.
3. A compound of claim 1 which is 3-benzoyl-1-methylpyrrolidine.
4. A compound of claim 1 which is 3-benzoyl-1-isopropylpyrrolidine.
13 14 12. A compound of claim 1 which is 1-[3-p-acetyl-o- References Cited methoxyphenoxy) -propyl] -3-benzoylpyrrolidine. UNITED STATES PATENTS 13. A compound of claim 1 which is 1-[3-(p-fluoron bemoyl) propyn 3 (p fiuorobenzoy1) pyrrolidine 3,318,908 5/1967 Sw1d1nsky et al 260J26.3
14. A compound of claim 1 Which is 3-benzoylpyrrol- 5 ALEX M AZEL Primary Examiner idine.
15. A compound of claim 1 which is 3-(p-fiuoroben- TOVAR Asslstant Exammer zoyl)-pyrrolidine.
16. A compound of claim 1 which is 3-(m-trifluoromethyl-benzoyl)-pyrro1idine. 1O 260326.3; 424274
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73841468A | 1968-06-20 | 1968-06-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US3489769A true US3489769A (en) | 1970-01-13 |
Family
ID=24967910
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US738414A Expired - Lifetime US3489769A (en) | 1968-06-20 | 1968-06-20 | 1-substituted-3-aroyl-pyrrolidines |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US3489769A (en) |
| JP (1) | JPS4830635B1 (en) |
| CA (1) | CA974528A (en) |
| DE (1) | DE1931027A1 (en) |
| FR (1) | FR2011338B1 (en) |
| GB (1) | GB1267600A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3835149A (en) * | 1971-11-30 | 1974-09-10 | Ciba Geigy Corp | 3-aroyl-alkenyleneimines |
| US4551540A (en) * | 1983-01-17 | 1985-11-05 | Borg-Warner Chemicals, Inc. | Substituted 2,5-dimethylpyrroles |
| US4551539A (en) * | 1983-01-17 | 1985-11-05 | Borg-Warner Chemicals, Inc. | Substituted 2,5-dimethylpyrroles |
| US5198449A (en) * | 1990-04-27 | 1993-03-30 | A. H. Robins Company Incorporated | N-substituted alpha-arylazacycloalkylmethanamines and their use as cardiovascular agents |
| WO2021219849A1 (en) | 2020-04-30 | 2021-11-04 | Idorsia Pharmaceuticals Ltd | Azetidin-3-ylmethanol derivatives as ccr6 receptor modulators |
| WO2023057548A1 (en) | 2021-10-07 | 2023-04-13 | Idorsia Pharmaceuticals Ltd | Ccr6 receptor modulators |
| WO2023073082A1 (en) | 2021-10-28 | 2023-05-04 | Idorsia Pharmaceuticals Ltd | Ccr6 receptor modulators |
| WO2023072924A1 (en) | 2021-10-26 | 2023-05-04 | Idorsia Pharmaceuticals Ltd | Ccr6 receptor modulators |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3318908A (en) * | 1962-06-18 | 1967-05-09 | Robins Co Inc A H | 3-cyanopyrrolidines |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE715405A (en) * | 1966-10-06 | 1968-11-18 |
-
1968
- 1968-06-20 US US738414A patent/US3489769A/en not_active Expired - Lifetime
-
1969
- 1969-06-18 GB GB30872/69A patent/GB1267600A/en not_active Expired
- 1969-06-19 CA CA054,804A patent/CA974528A/en not_active Expired
- 1969-06-19 DE DE19691931027 patent/DE1931027A1/en active Pending
- 1969-06-20 JP JP44048352A patent/JPS4830635B1/ja active Pending
- 1969-06-20 FR FR696920788A patent/FR2011338B1/fr not_active Expired
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3318908A (en) * | 1962-06-18 | 1967-05-09 | Robins Co Inc A H | 3-cyanopyrrolidines |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3835149A (en) * | 1971-11-30 | 1974-09-10 | Ciba Geigy Corp | 3-aroyl-alkenyleneimines |
| US4551540A (en) * | 1983-01-17 | 1985-11-05 | Borg-Warner Chemicals, Inc. | Substituted 2,5-dimethylpyrroles |
| US4551539A (en) * | 1983-01-17 | 1985-11-05 | Borg-Warner Chemicals, Inc. | Substituted 2,5-dimethylpyrroles |
| US5198449A (en) * | 1990-04-27 | 1993-03-30 | A. H. Robins Company Incorporated | N-substituted alpha-arylazacycloalkylmethanamines and their use as cardiovascular agents |
| WO2021219849A1 (en) | 2020-04-30 | 2021-11-04 | Idorsia Pharmaceuticals Ltd | Azetidin-3-ylmethanol derivatives as ccr6 receptor modulators |
| WO2023057548A1 (en) | 2021-10-07 | 2023-04-13 | Idorsia Pharmaceuticals Ltd | Ccr6 receptor modulators |
| WO2023072924A1 (en) | 2021-10-26 | 2023-05-04 | Idorsia Pharmaceuticals Ltd | Ccr6 receptor modulators |
| WO2023073082A1 (en) | 2021-10-28 | 2023-05-04 | Idorsia Pharmaceuticals Ltd | Ccr6 receptor modulators |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS4830635B1 (en) | 1973-09-21 |
| GB1267600A (en) | 1972-03-22 |
| FR2011338B1 (en) | 1973-01-12 |
| FR2011338A1 (en) | 1970-02-27 |
| CA974528A (en) | 1975-09-16 |
| DE1931027A1 (en) | 1970-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3576810A (en) | 1-substituted-3-(-4)-aroylpiperidines | |
| US3644414A (en) | 1-substituted-3-phenylpyrrolidines | |
| US3491093A (en) | Derivatives of 5 aminomethyl-4,5,6,7-tetrahydro-4-oxoindoles | |
| US3577440A (en) | 1-substituted-3-amido-pyrrolidines | |
| US3424762A (en) | Certain 3-ureidopyrrolidines | |
| US4423044A (en) | 3,4-Dihydro-5H-2,3-benzodiazepine derivatives and pharmaceutical use thereof | |
| US4194045A (en) | 1-(3,3-Diaryl-3-oxadiazolalkyl)-4-phenyl-4-piperidinomethanols and related compounds | |
| US3489769A (en) | 1-substituted-3-aroyl-pyrrolidines | |
| US4080330A (en) | Phenylindolines and process for their production | |
| US4101662A (en) | Method for inhibiting emesis and compositions therefor | |
| NZ197582A (en) | Dextrorotatory trans-4a,9b-5phenyl-2,3,4,4a,5,9b-hexahydro-1h-pyrido(4,3-b) indoles | |
| US4021552A (en) | 10-[ω-(BENZOYLPIPERIDINYL)ALKYL]PHENOTHIAZINES | |
| US3743645A (en) | 1-substituted-4-phenoxypiperidines | |
| US4324791A (en) | Heterocyclic antidiarrheal compositions & methods of use | |
| CA1068707A (en) | 4-piperidinylalkyl-3,3-diphenyl-2-pyrrolidinones | |
| US3499002A (en) | 1-carbamoyl-3-aroylpyrrolidines | |
| US3479370A (en) | Esters of 1-substituted-3-disubstituted-pyrrolidinemethanols | |
| US3459767A (en) | Aminomethylindoles | |
| US4315006A (en) | Benzoxocin derivatives having anxiolytic and anti-convulsant activities | |
| US3070628A (en) | 4-allyloxybenzylamines | |
| US3408396A (en) | alpha-cyclohexyl-3, 4-disubstituted-phenyl acetamides | |
| US3513166A (en) | 3-(omega-aminoalkyl)-4-substituted-1,3-benzoxazine-2-ones | |
| US3542794A (en) | 1-carbamoyl-4-phenoxypiperidines | |
| US3523950A (en) | Certain 4 - phenyl - 1,2,3,6 - tetrahydropyridyl-n-lower alkylene-ureas and derivatives | |
| US3513236A (en) | 5 - ((aryldehydropiperidinyl- and aryldehydropyrrolidinyl) - lower - alkyl) - 2-oxazolidinones in tranquilizing compositions and methods |